Glaukos Corporation (GKOS) Cut to Hold at BidaskClub

BidaskClub lowered shares of Glaukos Corporation (NYSE:GKOS) from a buy rating to a hold rating in a research note released on Monday morning.

A number of other research firms also recently weighed in on GKOS. Cantor Fitzgerald reiterated a buy rating and set a $60.00 price target (up previously from $54.00) on shares of Glaukos Corporation in a research note on Thursday, September 14th. Zacks Investment Research downgraded shares of Glaukos Corporation from a buy rating to a hold rating in a research note on Monday, July 24th. Roth Capital decreased their price target on shares of Glaukos Corporation from $60.00 to $54.00 and set a buy rating on the stock in a research note on Thursday, August 3rd. Piper Jaffray Companies reiterated a buy rating and set a $56.00 price target on shares of Glaukos Corporation in a research note on Thursday, August 3rd. Finally, BMO Capital Markets reiterated a buy rating and set a $54.00 price target on shares of Glaukos Corporation in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. Glaukos Corporation presently has an average rating of Buy and an average target price of $49.86.

Glaukos Corporation (NYSE GKOS) opened at 32.75 on Monday. The stock has a 50 day moving average of $36.29 and a 200-day moving average of $36.29. The company’s market capitalization is $1.13 billion. Glaukos Corporation has a 52-week low of $28.72 and a 52-week high of $52.49.

ILLEGAL ACTIVITY NOTICE: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://transcriptdaily.com/2017/09/21/glaukos-corporation-gkos-cut-to-hold-at-bidaskclub.html.

In related news, Director Orbimed Advisors Llc sold 325,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $37.93, for a total transaction of $12,327,250.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Thomas William Burns sold 1,212 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $41.25, for a total transaction of $49,995.00. The disclosure for this sale can be found here. Insiders sold a total of 980,200 shares of company stock worth $37,900,263 in the last 90 days. 16.40% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Navellier & Associates Inc lifted its position in Glaukos Corporation by 4.9% during the 2nd quarter. Navellier & Associates Inc now owns 33,307 shares of the medical instruments supplier’s stock worth $1,381,000 after buying an additional 1,567 shares in the last quarter. Public Employees Retirement System of Ohio lifted its position in Glaukos Corporation by 14.5% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 118,100 shares of the medical instruments supplier’s stock worth $4,898,000 after buying an additional 15,000 shares in the last quarter. Koch Industries Inc. acquired a new position in Glaukos Corporation during the 2nd quarter worth about $683,000. Ameritas Investment Partners Inc. lifted its position in Glaukos Corporation by 93.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,514 shares of the medical instruments supplier’s stock worth $104,000 after buying an additional 1,212 shares in the last quarter. Finally, California State Teachers Retirement System lifted its position in Glaukos Corporation by 54.0% during the 2nd quarter. California State Teachers Retirement System now owns 50,752 shares of the medical instruments supplier’s stock worth $2,105,000 after buying an additional 17,800 shares in the last quarter.

About Glaukos Corporation

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply